Cell-based drug testing; this world is not flat

Advanced Drug Delivery Reviews

Volumn 69-70, Issue , 2014, Pages

  Grainger, David W ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; DRUG METABOLITE;

BIOLOGICAL MODEL; BIOREACTOR; BIOTECHNOLOGY; BREAST CANCER; CELL CULTURE; CELL TYPE; COCULTURE; CULTURE TECHNIQUE; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TOXICITY; EDITORIAL; EPITHELIUM CELL; HUMAN; IN VITRO STUDY; KIDNEY DISEASE; LYMPHOID TISSUE; MONOLAYER CULTURE; NANOMEDICINE; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; TISSUE ENGINEERING; TISSUE STRUCTURE; TOXICITY TESTING; ANIMAL; PROCEDURES; TRENDS;

ANIMALS; CELL CULTURE TECHNIQUES; DRUG DISCOVERY; HUMANS;

EID: 84899938064     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.04.001     Document Type: Editorial

References (27)

1. Munos B. Lessons from 60years of pharmaceutical innovation. Nat. Rev. Drug Discov. 2009, 8:959-968.
2. Adams D.J. The Valley of Death in anticancer drug development: a reassessment. Trends Pharmacol. Sci. 2012, 33(4):173-180.
3. Paul S.M., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9:203-214.
4. Wehling M. Opinion. Assessing the translatability of drug projects: what needs to be scored to predict success?. Nat. Rev. Drug Discov. 2009, 8:541-546.
5. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
6. FasterCures Crossing Over the Valley of Death, FasterCures/The Center for Accelerating Medical Solutions 2011, http://www.fastercures.org/documents/file/Valley%20of%20Death%20-%20Translational%20Research(1).pdf (accessed March 1, 2014).
7. Butler D. Translational research: crossing the valley of death. Nature 2008, 453:840-842.
8. Coller B.S., Califf R.M. Traversing the Valley of Death: a guide to assessing prospects for translational success. Sci. Transl. Med. 2009, 1:1-5.
9. Astashkina A., Grainger D.W. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. Adv. Drug Deliv. Rev. 2014, 69--70:1-18.
10. Ranga A., Gjorevski N., Lutolf M.P. Drug discovery through stem cell-based organoid models. Adv. Drug Deliv. Rev. 2014, 69-70:19-28.
11. Thoma C.R., Zimmermann M., Agarkova I., Kelm J.M., Krek W. 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Adv. Drug Deliv. Rev. 2014, 69-70:29-41.
12. Weigelt B., Ghajar C.M., Bissell M.J. The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv. Drug Deliv. Rev. 2014, 69-70:42-51.
13. Håkanson M., Cukierman E., Charnley M. Miniaturized pre-clinical cancer models as research and diagnostic tools. Adv. Drug Deliv. Rev. 2014, 69-70:52-66.
14. DesRochers T.M., Palma E., Kaplan D.L. Tissue-engineered kidney disease models. Adv. Drug Deliv. Rev. 2014, 69-70:67-80.
15. Mathes S.H., Ruffner H., Graf-Hausner U. The use of skin models in drug development. Adv. Drug Deliv. Rev. 2014, 69-70:81-102.
16. Giese C., Marx U. Human immunity in vitro - Solving immunogenicity and more. Adv. Drug Deliv. Rev. 2014, 69-70:103-122.
17. LaBarge M.A., Parvin B., Lorens J.B. Molecular deconstruction, detection, and computational prediction of microenvironment-modulated cellular responses to cancer therapeutics. Adv. Drug Deliv. Rev. 2014, 69-70:123-131.
18. Ebrahimkhani M.R., Neiman J.A.S., Raredon M.S.B., Hughes D.J., Griffith L.G. Bioreactor technologies to support liver function in vitro. Adv. Drug Deliv. Rev. 2014, 69-70:132-157.
19. Esch M.B., Smith A.S.T., Prot J.-M., Oleaga C., Hickman J.J., Shuler M.L. How multi-organ microdevices can help foster drug development. Adv. Drug Deliv. Rev. 2014, 69-70:158-169.
20. McGivern J.V., Ebert A.D. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments. Adv. Drug Deliv. Rev. 2014, 69-70:170-178.
21. Roth A., Singer T. The application of 3D cell models to support drug safety assessment: Opportunities & challenges. Adv. Drug Deliv. Rev. 2014, 69-70:179-189.
22. Berg E.L., Hsu Y.-C., Lee J.A. Consideration of the cellular microenvironment: Physiologically relevant co-culture systems in drug discovery. Adv. Drug Deliv. Rev. 2014, 69-70:190-204.
23. Seo B.R., DelNero P., Fischbach C. In vitro models of tumor vessels and matrix: Engineering approaches to investigate transport limitations and drug delivery in cancer. Adv. Drug Deliv. Rev. 2014, 69-70:205-216.
24. Vyawahare S., Zhang Q., Lau A., Austin R.H. In vitro microbial culture models and their application in drug development. Adv. Drug Deliv. Rev. 2014, 69-70:217-224.
25. Schmitt S.M., Gull M., Brändli A.W. Engineering Xenopus embryos for phenotypic drug discovery screening. Adv. Drug Deliv. Rev. 2014, 69-70:225-246.
26. O'Reilly L.P., Luke C.J., Perlmutter D.H., Silverman G.A., Pak S.C. C. elegans in high-throughput drug discovery. Adv. Drug Deliv. Rev. 2014, 69-70:247-253.
27. Emmert M.Y., Hitchcock R.W., Hoerstrup S.P. Cell therapy, 3D culture systems and tissue engineering for cardiac regeneration. Adv. Drug Deliv. Rev. 2014, 69-70:254-269.